Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic AdV/CMV/EBV-specific T lymphocytes

A preparation of human leukocyte antigen (HLA)-matched or HLA-mismatched, allogeneic CD4+ and CD8+ T lymphocytes, ex vivo incubated with synthetic peptides of the viral antigens of the three human viruses adenovirus (AdV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with potential antiviral activity. Upon administration of the allogeneic AdV/CMV/EBV-specific T lymphocytes after allogeneic hematopoietic stem cell transplantation (HSCT), these T lymphocytes may kill AdV, CMV, and/or EBV-infected cells, and may prevent or reduce the severity of viral infections by these pathogens.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic AdV/CMV/EBV multi-virus-specific T lymphocytes

allogeneic AdV/CMV/EBV-specific T lymphocytes

Search NCI's Drug Dictionary